INTRODUCTION: The widespread use of prostate cancer screening has led to a stage migration resulting in an increase in the diagnosis of low-risk disease, which currently accounts for 40-50% of diagnosed forms.
New therapeutic strategies have been developed in order to minimize the risk of overtreatment.
METHODS: A systematic review of the literature over the past 20 years was performed using the Medline database. The literature selection was based on evidence and practical considerations.
RESULTS: Low-risk tumors are conventionally defined by the d'Amico classification. The use of multiparametric MRI helps to better characterize these tumors. The contribution of molecular biology remains to be determined in clinical practice. Novel therapeutic options for low-risk disease are currently being evaluated.
CONCLUSION: The new therapeutic strategies are evolving. They seek to reduce overtreatment without compromising oncological success.
Written by:
Rozet F, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Renard-Penna R, Richaud P, Salomon L, Soulié M. Are you the author?
Université Paris Descartes, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Comité de cancérologie de l'AFU, France; Hôpital Nord, CHU de Marseille, 416, chemin Madrague-Ville, 13015 Marseille, France; Comité de cancérologie de l'AFU, France; Institut Curie, 26, rue Ulm, 75005 Paris, France; Comité de cancérologie de l'AFU, France; CHU de Dijon, 1, boulevard Jeanne-d'Arc, 21000 Dijon, France; Comité de cancérologie de l'AFU, France; CHU Bretonneau, 2, boulevard Tonnellé, 37000 Tours, France; Comité de cancérologie de l'AFU, France; Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Comité de cancérologie de l'AFU, France; Hôpital Cochin, 27, rue Faubourg Saint-Jacques, 75014 Paris, France; Comité de cancérologie de l'AFU, France; Hôpital Pitié-Salpêtrière, 47, boulevard de l'hôpital, 75013 Paris, France; Comité de cancérologie de l'AFU, France; Institut Bergonié, 229, cours Argonne, 33000 Bordeaux, France; Comité de cancérologie de l'AFU, France; Hôpital Henri-Mondor, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France; Comité de cancérologie de l'AFU, France; Hôpital de Rangueil, CHU de Toulouse, 1, avenue Professeur Jean-Poulhès, 31059 Toulouse cedex 9, France; Comité de cancérologie de l'AFU, France.
Reference: Prog Urol. 2015 Jan;25(1):1-10.
doi: 10.1016/j.purol.2014.10.007
PubMed Abstract
PMID: 25454776
Article in French.